PLA-based nanoparticles are used by conjugating antibodies (e.g., trastuzumab, cetuximab) that target cancer cell surface receptors such as HER2 and EGFR (epidermal growth factor receptor) to their surface [124]. The gene discussed is ERBB2; the disease is cancer.